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Cyclin-dependent kinases 4 and 6 are complexed with many small cellular proteins in
vivo. We have isolated cDNA sequences, INK4d, encoding a 19-kDa protein that is
associated with CDK6 in several hematopoietic cell lines. p19 shares equal similarity and
a common ancestor with other identified inhibitors of the p16/INK4 family. p19 interacts
with and inhibits the activity of both CDK4 and CDK6 and exhibits no detectable
interaction with the other known CDKs. p19 protein is present in both cell nuclei and
cytoplasm. The p19 gene has been mapped to chromosome l9pl3.2, and the level of its
mRNA expression varies widely between different tissues. In contrast to p21 and p27
whose interaction with CDK subunits is dependent on or stimulated by the cyclin
subunit, the interaction of p19 and p18 with CDK6 is hindered by the cyclin protein.
Binary cyclin D1-p18/p19 or cyclin Dl-CDK6 complexes are highly stable and cannot be
dissociated by excess amounts of cyclin Dl or pl9/pl8 proteins, suggesting that p16
inhibitors and D cyclins may interact with CDKs 4 and 6 in a competing or potentially
mutually exclusive manner.
INTRODUCTION
The eukaryotic cell cycle is regulated by the sequential
formation, activation, and subsequent inactivation of a
series of structurally related serine/threonine protein
kinases, CDKs (cyclin-dependent kinases) (see two re-
cent reviews in Sherr, 1994; Hunter and Pines, 1994).
The enzymatic activity of a CDK is regulated by at
least three different mechanisms: cyclin binding and
activation, subunit (inhibitory and activating) phos-
phorylation, and inhibition by a CDK inhibitor. In
mammalian cells, there exists at least two distinct
families of CDK inhibitors, represented by two proto-
type CDK inhibitors p21 and p16. p21 (also variously
known as CIP1, WAF1, SDI1, CAP20, PIC1, and
' Corresponding author.
CDKN1), first identified in normal human fibroblasts
as a component of quaternary cyclin D-CDK com-
plexes that also contain proliferating cell nuclear an-
tigen (PCNA; Xiong et al., 1992), is a potent inhibitor of
most, if not all, cyclin-CDK enzymes (Gu et al., 1993;
Harper et al., 1993; Xiong et al., 1993a). The p21 family
of CDK inhibitors currently contains three related
genes, p21, p27KiPl (Polyak et al., 1994; Toyoshima and
Hunter, 1994), and p57 p2 (Lee et al., 1995; Matsuoka
et al., 1995). Both p27 and p57 share significant amino
acid homology with p21 in their amino-terminal re-
gion and, like p21, interact with and inhibit the activ-
ity of a variety of cyclin-CDK complexes (Polyak et al.,
1994; Toyoshima and Hunter, 1994; Lee et al., 1995;
Matsuoka et al., 1995). In addition to inhibiting the
kinase activity of cyclin-CDK enzymes, p21 can also
regulate the cell cycle through two other separate
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mechanisms: by interacting with PCNA through a
carboxyl-terminal domain in the absence of cyclin and
CDK proteins to inhibit PCNA-dependent DNA
replication (Flores-Rozas et al., 1994; Waga et al.,
1994; Chen et al., 1995; Luo et al., 1995; Nakanish et
al., 1995; Warbrick et al., 1995), and by blocking the
activating phosphorylation of CDKs by CDK-acti-
vating kinase (CAK; Kato et al., 1994a; Aprelikova et
al., 1995). Expression of the p21 gene can be induced
by a wide range of cell growth regulatory signals,
including the DNA damage and tumor suppressor
p53, the antimitogenic cytokine growth factor trans-
forming growth factor (TGF)-,B, cellular senescence,
and cell differentiation, supporting a broad biolog-
ical role for the p21 CDK inhibitor (reviewed by
Sherr and Roberts, 1995).
Four genes have been isolated as members of the
p16 family of CDK inhibitors as follows: p16 (also
known as INK4a, MTS1, CDK4L, and CDKN2; Ser-
rano et al., 1993; Kamb et al., 1994; Nobori et al.,
1994), p15 (also known as MTS2, INK4b, and p14
(Guan et al., 1994; Hannon and Beach, 1994; Kamb et
al., 1994), p18 (INK4c; Guan et al., 1994; Hirai et al.,
1995), and p19 (this study). Two members of this
family, p16 and p15, are homozygously deleted at a
high frequency in a wide variety of human tumor-
derived cell lines (Kamb et al., 1994; Nobori et al.,
1994) and several specific types of primary tumors
(reviewed in Sherr, 1994; Hunter and Pines, 1994),
indicating a tumor suppression function of p16. The
major, if not only, inhibitory targets of the p16
family are CDK4 and CDK6 (Serrano et al., 1993;
Xiong et al., 1993b; Guan et al., 1994; Hannon and
Beach, 1994). Their preferential association with
D-type cyclins, substrate preference, and the timing
of the onset of their kinase activity have strongly
implicated both CDK4 and CDK6 as physiological
kinases for the retinoblastoma susceptibility gene
product pRB, whose growth-suppressing activities
are known to be down-regulated by cell cycle-
dependent phosphorylation (for a recent review, see
Sherr, 1994). Ectopic expression of p18 or p16 sup-
presses cell growth with a correlated dependence on
endogenous wild-type pRb (Guan et al., 1994; Koh
et al., 1995; Lukas et al., 1995; Sherr and Roberts,
1995), suggesting a potential mechanism by which
members of the p16 family inhibit cell growth, in-
hibiting the activity of CDK6 and CDK4 kinases,
thereby preventing the phosphorylation of pRb, and
keeping pRb in its active growth-suppressing state.
To elucidate the mechanism by which the activities
of CDK4 and CDK6 are regulated during the cell
cycle and cell growth, we have isolated and charac-
terized a novel CDK4 and CDK6 specific inhibitor,
p19, and further investigated the interaction of
the two families of CDK inhibitors and their CDK
targets.
MATERIALS AND METHODS
Cell Culture and Immunochemistry Procedures
ML1 (a human myeloid leukemia cell line), CEM (a human acute
lymphoblastic leukemia cell line, ATCC CCL 119), and Jurkat (a
human acute T cell leukemia cell line, ATCC TIB 153) were cultured
in RPMI 1640 supplemented with 10% fetal bovine serum and
antibiotics. Most of the antibodies used and procedures for [35SIme-
thionine metabolic labeling, immunoprecipitation, and SDS-PAGE
have been described previously (Xiong et al., 1993b; Guan et al.,
1994; Jenkins and Xiong, 1995).
Rabbit polyclonal anti-human p19 peptide antibody was raised
against a synthetic peptide CDLVDILOCHMVAPL with the under-
lined region corresponding to the carboxyl-terminal region of hu-
man p19. Two additional rabbit polyclonal antibodies were raised
against full length human p19 protein-one against a purified native
GST-p19 fusion protein and the other against p19 denatured by
SDS-PAGE. All three were subsequently affinity purified. The anti-
bodies against human p19 do not exhibit detectable cross-reactivity
with any other members of the p16 family in immunoprecipitation
or immunoblotting, nor do they cross-react with any other known
cell cycle proteins.
Nucleic Acid Procedures
To isolate p16-/p18-related genes, three degenerate oligonucleo-
tides were synthesized based on the amino acid sequences
conserved between p16 (Serrano et al., 1993), p14 (Guan et al.,
1994; Hannon and Beach, 1994), and p18 (Guan et al., 1994). The
nucleotide sequences for the 5' primers, A and B, are CGGAATTC-
ACNGCNGCNGCN(A,C)GNGG encoding AAARG, and CGGAA-
TTC(C,G)CN(A,C,T)TNCA(A,G)GTNATG encoding ALQVM, re-
spectively. The 3' primer is CGGAATTCAGNGT(A,G)-TCNA(A,G)-
(A,G)AANCC, which encodes GFLDT. An EcoR I restriction site was
introduced into each primer (underlined sequence) for the conve-
nience of subsequent subcloning. A pair of primers were used to
amplify potential p16-/p18-related sequences from cDNA tem-
plates prepared from human B cells, leukocytes, testis, and brain by
polymerase chain reaction (PCR) for 35 cycles at 94'C for 1 min,
52'C for 1 min, and 72'C for 1 min. The PCR products were resolved
on a 2.5% Nusieve (FMC) agarose gel. DNA fragments with approx-
imately 150-250 bp were purified using Geneclean (Bio 101, La Jolla,
CA) and used as templates for a second round of PCR. PCR prod-
ucts were again resolved on a 3% Nusieve agarose gel and DNA
fragments of approximately 150 bp were gel purified and subcloned
into the EcoR I site of M13 mpl9 for sequencing. Of 64 M13 sub-
clones sequenced, one (derived from leukocytes) was found to
contain an insert that encodes a potential p16-/p18-related gene,
and this 150-bp insert was then labeled by random primer labeling
methods and used as a probe to screen a human spleen cDNA
library. Of 10 positive cDNA clones isolated from this screen, the
longest one, S2, was completely sequenced.
For the Northern analysis, 2 ,tg poly(A)+ RNA was isolated from
different human tissues, resolved on a 1.2% agarose gel, and trans-
ferred to a nylon membrane (Clontech, Cambridge, UK). The 1.3-kb
DNA fragment of full length human or mouse p19 cDNA was
labeled by the random priming labeling method and used as a
probe for Northern hybridization. The same blot was stripped and
re-hybridized with a 0.6-kb DNA fragment corresponding to the
coding region of human p18 that detects only two major mRNA
transcripts and with a 2-kb full length human p21 cDNA fragment
as probes (Xiong et al., 1993a; Guan et al., 1994).
Kinase Assay
Reconstitution of active CDK4 and CDK6 kinases was performed by
methods similar to those previously described (Kato et al., 1994b).
Glutathione S-transferase (GST) fusion proteins containing human
cyclin D2, CDK4, and CDK6 were constructed by placing the entire
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coding region of each sequence into pGEX-KG, transforming into
Escherichia coli strain TG1, and purifying the resultant GST fusion
proteins following published procedures (Guan and Dixon, 1991).
Two micrograms of purified GST-cyclin D2 protein were mixed
with 2 ,tg of purified GST-CDK4 or GST-CDK6. The mixtures were
incubated with cell lysate (50 ,ll) derived from 106 exponentially
growing Jurkat cells that were lysed in a buffer containing 80 mM
sodium-,B-glycerophosphate, 5 mM N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES), pH 7.4, 15 mM MgCl2, 0.3 mM
sodium orthovanadate, 1 mM benzamidine, 0.5 mM phenylmethyl-
sulfonyl fluoride, 10 ,ug/ml trypsin inhibitor, 2 ,tg/ml pepstatin, 2
jig/ml chymostatin, 10 j,g/ml aprotinin, and 2 mM dithiothreitol.
Cells were briefly sonicated and centrifuged at 4°C for 10 min at
maximum speed in a microcentrifuge. ATP was added to the mix-
ture of GST fusion proteins and Jurkat cell lysate at a final concen-
tration of 1 mM. The reaction was incubated at room temperature
for 1 h and centrifuged for 5 min. The activated GST-cyclin D2/
GST-CDK4 or CDK6 was recovered from the mixture on glutathione
agarose beads and eluted in 50 ,ul of kinase assay buffer (50 mM
HEPES, pH 7.0, 10 mM MgCl2, 1 mM dithiothreitol, 10 ,uM ATP)
containing 10 mM glutathione. One-fourth (approximately 0.5 ,ug)
of the activated CDK4 or CDK6 enzymes was used to phosphorylate
1 jig of purified GST-Rb C-terminal fusion protein in a final volume
of 20 ,ul with addition of 10 jiCi [y-32P]ATP at 30°C for 1 h. The
reaction was terminated by adding 20 ,ul of 2x SDS sample buffer,
and one-half of the reaction was analyzed by SDS-PAGE followed
by autoradiography. CDC2 and CDK2 kinase activities were as-
sayed on anti-CDC2 and anti-CDK2 immunoprecipitates derived
from Jurkat cells as described previously (Guan et al., 1994). To
assay for the inhibitory activity of p19, the full length p19 coding
region was subcloned into pGEX-KG, and GST-p19 fusion protein
was purified as described (Guan and Dixon, 1991). Purified GST,
GST-p19, or control buffer was added to the activated CDK4-cyclin
D2 or CDK6-cyclin D2 before the addition of GST-Rb substrate and
[y-32P]ATP.
Chromosomal Localization
Approximately 2 jig of DNA bearing a 1.3-kb full length p19 cDNA
insert was nick translated and hybridized to human metaphase
chromosomes as described previously (Guan et al., 1994). Addition-
ally, the biotinylated p19 cDNA probe was co-hybridized to human
metaphase spreads with a digoxigenin-labeled Alu consensus 77
mer (GM009; Matera and Ward, 1992). After hybridizing overnight,
the slides were washed in 50% formamide/2x SSC at 37°C, fol-
lowed by washes in 1 x SSC at 60°C. The p19 probe was detected
with fluorescein isothiocyanate (FITC)-conjugated avidin, while Alu
oligo was detected with rhodamine-conjugated anti-digoxigenin.
The cytogenetic location in band l9pl3, determined by R banding,
was confirmed and further localized to 19p13.2 by averaging FL pter
measurements from four metaphase spreads (range 0.16-0.23; me-
dian 0.2).
Transfection and Immunofluorescence Staining
Transfection of Swiss 3T3 cells with pCMV-p19 was performed
using Lipofectamine methods (Life Technologies, Gaithersburg,
MD). Swiss 3T3 cells cultured on coverslips in 24-well culture plates
were washed twice with 1 ml of ice-cold phosphate-buffered saline
(PBS) and fixed for 10 min at room temperature in 1 ml of 3%
formaldehyde diluted in PBS followed by 1 ml of a 1:1 mixture of
methanol and acetone for 5 min with gentle shaking. After washing
three times with 1 ml PBS, the coverslips were incubated for 60 min
with the two different affinity-purified anti-p19 antibodies (anti-p19
and anti-GST-p19, both 1:100 dilution) in 0.2 ml of PBS supple-
mented with 1% bovine serum albumin, 1 mg/ml thyroglobulin,
and 0.1% saponin (Sigma, St. Louis, MO), and then washed four
times with PBS plus 0.1% saponin. The coverslips were incubated
with anti-rabbit IgG Texas Red conjugate (1:100) for 45 min in the
dark in 0.2 ml of PBS containing 0.1% saponin and 1% bovine serum
albumin and washed four times, 2 min each with 1 ml of PBS plus
0.1% saponin followed by two washes with PBS, 2 min each. 4,6-
diamidino-2-phenylindole (DAPI, 1 jig/ml; Sigma) was added in
the second wash to stain nuclei. Finally, the coverslips were
mounted with 4 ,ul of buffered glycerol (10% PBS, 0.1% p-phe-
nylenediamine, and 90% glycerol) on a glass slide, sealed with nail
polish, and examined by fluorescence microscopy (Zeiss, Thorn-
wood, NY).
In Vitro Translation and In Vitro Binding Assay
In vitro translation and in vitro binding assays were carried out as
described previously (Guan et al., 1994). For in vitro binding exper-
iments, each mixing step was 60 min at room temperature. The
mixtures were immunoprecipitated in 200 jil of NP-40 lysis buffer
(the same as that used in immunoprecipitation) with anti-CDK6
(Guan et al., 1994). For the dissociation experiment shown in Figure
8D, 1 ,ul of purified p19 protein diluted with extraction buffer (50
mM NaCl/50 mM Tris-HCl, pH 7.5/1 mM EDTA/10% glycerol) to
different concentrations, as indicated on the top of each lane, was
added to the mixture after the mixing of in vitro-translated CDK6
with cyclin Dl for 20 min at room temperature.
RESULTS
Cloning of p19
We and others have previously found that CDK4 and
CDK6 associate with, in addition to pl6INK4a/MTS1,
many small cellular proteins, and have isolated cDNA
sequences encoding pl4/pl5MTs2/INK4b and p18
(Guan et al., 1994; Hannon and Beach, 1994; Li et al.,
1994b). Most of these small CDK4- and CDK6-associ-
ated proteins are likely to encode novel members of
the p16 family of CDK inhibitors. Degenerate oligo-
nucleotides were designed based on regions con-
served among the p15, p16, and p18 sequences, and
used as primers to amplify cDNA sequences from
several different cell lines in an attempt to isolate
genes encoding novel p16- and p18-related CDK4 and
CDK6 inhibitors (see MATERIALS AND METHODS).
One PCR fragment identified in cDNA prepared from
human leukocytes encodes a potentially novel p16-
related molecule and was used as a probe to screen a
human spleen cDNA library to obtain the full length
sequence. The longest lambda cDNA clone, S2, was
completely sequenced and found to contain a 1254-bp
insert with a short poly A tail preceded by a putative
polyadenylation signal (Figure 1A). Conceptual trans-
lation of this clone revealed an apparent full-length
open reading frame with 166 amino acid residues
starting at nucleotide 140 preceded by an in-frame
termination codon present 54 bp 5' to the initiating
methionine. The predicted molecular weight of this
protein is 17,689 Da, but its apparent molecular weight
as seen in SDS-PAGE is 19 kDa (p19, see Figure 3A).
p19 shares similar protein sequence identity with the
other three previously identified CDK4- and CDK6-
specific inhibitors: 40% protein sequence identity to
p16INK4a/MTS1 over a 154-amino acid region, 44% topl4/pl5MTS2/INK4b over a 133-amino acid region, and
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p19: cDNA AACCGCTTCGGCAAGACGGCGCTGCAG GTCATCATGTTTGGCAGCACC
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pl5:cDNA AACCGTTTCGGGAGGCGCGCGATCCAG
p15:Genomic AACCGTTTCGGGAGGCGCGCGATCCAGGTCTG.




L70 Figure 1. DNA and protein se-
quence of the human p19 gene.
254 (A) Nucleotide and amino acid
sequences of human p19. Num-
bers for both nucleotides and
amino acids are given, and the
stop codon is indicated by an as-
terisk. (B) Amino acid sequence
comparison of p19 with the
other three p16 family genes,
p14/pl5m'2/INK4b (Guan et al.,
1994; Hannon and Beach, 1994),
p16 (Serrano et al., 1993), and p18
(Guan et al., 1994). The complete
coding regions of the four inhibi-
tor proteins were aligned, and
amino acid residues identical in
all four sequences are in bold.
Several small gaps were intro-
duced as represented by hyphens.
(C) An intron interrupts all four
isolated INK4 genes at the same
position. Partial characterization
of the genomic structure of p19 by
DNA sequencing and comparison
with p19 cDNA revealed an in-
tron located at a position corre-
sponding to nucleotides 280-281
of the p19 cDNA presented in Fig-
ure 1A. The coding regions of the
other three INK4 genes, p15, p16,
and p18 are also interrupted by
an intron at the identical position
(Guan et al., 1994; Kamb et al.,
1994). The accession number for
this sequence is U40343.
43% to p18 over a 165-amino acid region (Figure 1B).
As first noticed in p16, p19 also contains tandem
ankyrin repeats like other members of the family (Ser-
rano et al., 1993). In addition, like p18 (Guan et al.,
1994), p19 also shares significant protein sequence
identity with the Notch genes, with 35% identity over
the 107 residues to the human Notch homologue,
TAN1, protein. The functional significance of the pro-
tein sequence similarity between the Notch gene prod-
ucts and the p16 family of CDK inhibitors, in partic-




ular p18 and p19, remains unclear. After submission of
this study, two articles appeared that reported the
isolation of both the murine and human p19 CDK
inhibitor (Chan et al., 1995; Hirai et al., 1995). The p19
protein sequence as presented in Figure 1A is nearly
identical to that reported by Chan et al. (1995) except
in two places, at amino acid residues 11 and 12 (AG-
DRLS versus AGT-LS) and at residue 159 (ILQGH
versus ILPGH). In both discrepant areas, the sequence
presented in Figure 1A is identical to the genomic
sequence determined from a clone isolated from a
human placenta genomic library (our unpublished re-
sults). Human p19 is very closely related to mouse p19
(Chan et al., 1995; Hirai et al., 1995). Following the
genetic nomenclature first used for the p16 gene (Ser-
rano et al., 1993), p19 can be designated as INK4d.
Using the p19 cDNA fragment as the probe, we have
isolated lambda clones containing the p19 gene from a
human placental genomic DNA library and partially
determined the genomic structure of p19 (Figure 1C).
DNA sequencing and comparison with the p19 cDNA
revealed an intron located at a position corresponding
to nucleotides 280-281 of the p19 cDNA presented in
Figure 1A. The coding regions of the pl5, pl6, and pl8
genes are also interrupted by an intron at the identical
position (Guan et al., 1994). These results demonstrate
that all four isolated INK4 genes were evolved from a
common ancestor, and thereby constitute a family of
evolutionarily related genes.
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p19 Specifically Interacts with CDK4 and CDK6
To assess the specificity of p19's interaction with
known CDKs, six CDK proteins were in vitro trans-
lated with [35S]methionine labeling and mixed with
similarly in vitro-translated p19 protein. The mixtures
were then immunoprecipitated with antisera specific
to each CDK and resolved by SDS-PAGE. p19 was
coprecipitated with CDK4 and CDK6, but not with the
other CDK proteins (Figure 2B). Reciprocally, in vitro-
translated, [35S]-labeled CDK proteins were mixed
with excess amounts of purified GST-p19 fusion pro-
tein and recovered from the different mixtures on
glutathione-agarose beads. Consistently, CDK4 and
CDK6, but not the other CDK proteins, were bound to
and recovered with the GST-p19 protein (Figure 2C).
In Vivo Association of p19 with CDK6
To establish the in vivo association of p19 with CDK4
and CDK6 and to determine whether p19 encoded the
CDK6-associated, p18-related p20 protein previously
identified in several human leukemia cell lines (Guan
et al., 1994), [35S]methionine-labeled lysates were pre-
pared from ML1 human myeloid leukemia cells and
immunoprecipitated with antibodies specific to CDK4,
CDK6, and p19 (Figure 3A). The CDK6-associated 20-







Figure 2. Interaction of p19 with CDKs. (A) The six CDK proteins
were synthesized in vitro in rabbit reticulocyte lysate with [35S]me-
thionine labeling and adjusted to an equivalent amount. (B) Equal
amounts of each of the six in vitro-translated CDK proteins were
mixed with similarly in vitro-translated p19 protein. The mixtures
were immunoprecipitated with antibody specific to each CDK pro-
tein and precipitates were resolved by SDS-PAGE followed by
autoradiography. (C) Purified GST-p19 fusion proteins were incu-
bated with equal amounts of each of the six different in vitro-
translated [35S]methionine-labeled CDK proteins and recovered
from the different mixtures on glutathione-agarose beads. Proteins
bound to GST-p19 were resolved by SDS-PAGE followed by auto-
radiography. Control GST proteins did not bind to any CDK pro-
teins (our unpublished observation).
translated p19 protein (our unpublished results) and
with p19 protein immunoprecipitated by the anti-p19
antibody (Figure 3A). When the p20 band from the
anti-CDK6 immunoprecipitate was excised from an
SDS-polyacrylamide gel, partially digested with V8
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Figure 3. In vivo association of p19 with CDK6. (A) [35S]methionine-labeled lysates were prepared from a myeloid leukemia cell line, ML1.
Lysates were immunoprecipitated with anti-CDK4, anti-CDK6, and anti-p19 antibodies, with or without pre-incubation with a competing
antigen peptide. The immunoprecipitated polypeptides were resolved on a 15% SDS-polyacrylamide gel. The mobility of protein molecular
weight standards (Life Technologies) and relevant proteins are indicated. (B) Comparison of V8 proteolysis patterns of p19 proteins derived
from anti-CDK6 immunoprecipitate (lanes 1-3) and in vitro translation (lanes 4-6). (C) Coupled immunoprecipitation and immunoblotting.
ML1 cell lysates were immunoprecipitated with antibodies as indicated. The immunoprecipitates were subjected to SDS-PAGE and
immunoblotted with four different antibodies as indicated on the top of each panel.
protease, and compared with similarly V8-digested in
vitro-translated p19 (Figure 3B), they displayed iden-
tical proteolysis patterns, confirming the in vivo asso-
ciation of p19 with CDK6. To maintain consistency
with the molecular weight identification reported after
the submission of this manuscript (Chan et al., 1995;
Hirai et al., 1995), the 20-kDa protein is hereafter re-
ferred to as p19. In the over twenty cell lines that have
been examined, we primarily detected p19 in hemato-
poietic cell lines in association with CDK6.
As further confirmation of the in vivo association of
p19 with CDK6 and to assess the relative contribution
of different INK4 proteins to the inhibition of CDK4/6
in a given cell type, we performed coupled immu-
noprecipitation-immunoblotting (IP-Western) experi-
ments in ML1 cells. ML1 cells expressed a much
higher level of CDK6 than CDK4 (Figure 3C, lanes 1
and 3), comparable levels of p18 and p19 (Figure 3C,
lanes 11 and 16), and p16 and p15 were undetectable
(our unpublished results). There was no detectable
interaction between CDK4 and p18 or CDK4 and p19
in ML1 cells as determined by either [35S]methionine-
labeling immunoprecipitation or IP-Western (Figure
3). Approximately three times more p18 than p19 was
present in CDK6 immunoprecipitates (Figure 3C,
lanes 5 and 6). Reciprocally, there is more CDK6 pro-
tein co-precipitated with p18 than with p19 (Figure
3C, lanes 9 and 14; note that all three panels of Figure
3C were derived from a single experiment and the
same exposure). These results suggest that p18 may
have a higher affinity for, and is therefore a more
potent inhibitor of, CDK6 than p19 in cells such as
ML1 that express similar levels of both proteins.
p19 Inhibits CDK4 and CDK6 Kinase Activity
To directly test whether p19 inhibits the kinase activity
of CDK6 and CDK4, we reconstituted the kinase ac-
tivity of both CDK6 and CDK4 (see MATERIALS
AND METHODS). Purified GST-CDK4 or GST-CDK6
protein was mixed with purified GST-cyclin D2 pro-
tein in vitro. The mixtures of CDK4- and CDK6-cyclin
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D2 were activated by incubating with Jurkat cell lysate
and used to assay p19 inhibitory activity using puri-
fied GST-Rb fusion protein as a substrate (see MATE-
RIALS AND METHODS). Purified GST-p19 protein
(Figure 4A, lanes 3 to 7), but neither control buffer (our
unpublished results) nor GST protein (Figure 4, lane
8), effectively inhibits the kinase activity of CDK6 in a
dosage-dependent manner. Although p19 was not de-
tected in association with CDK4 in vivo in MLI cells
(Figure 3), it inhibited CDK4 kinase activity in vitro
with a similar potency as it inhibited CDK6 (Figure
4B). Forty nanograms of p19 protein or less was suf-
ficient to completely inhibit the kinase activity recon-
stituted from approximately 100 ng CDK4-cyclin D2
and CDK6-cyclin D2, presumably because only a frac-
tion of the CDK4/6-cyclin D2 complexes was acti-
vated. The technical difficulties involved in determin-
ing the active portion of the recombinant proteins
expressed and purified from bacteria prevented us
from determining the stoichiometry of p19's inhibi-
tory interaction with its target kinases and the relative
affinity of p19 and other INK4 proteins for CDK4 and
CDK6. Consistent with the in vitro binding assays
(Figure 2), p19 has no detectable effect on the kinase
activity of either immunoprecipitated CDC2 or CDK2
(Figure 4C). CDC2 and CDK2 associate with multiple
cyclins (cyclin A, BI, B2, Ds, and E) to constitute
several distinct cyclin-CDK enzymes. These data dem-
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Tissue Specificity of p19 mRNA Expression
Northern blot analysis was carried out to determine
the expression of p19 mRNA in sixteen different hu-
man tissues. Under high stringency conditions, the
full length p19 cDNA probe detected a single band of
approximately 1.4 kb (Figure 5). For comparison, the
same blot was striped and rehybridized with a p18 or
p21 probe. Unlike p21 and p27 whose mRNAs accu-
mulate in most human tissues with much less varia-
tion (Polyak et al., 1994; Guan et al., 1994; Figure 5), the
level of p19 and p18 mRNAs varied significantly be-
tween different tissues. The highest level of p19
mRNA was observed in thymus, peripheral blood
leukocytes, and brain, and moderate levels were
present in spleen, testis, skeletal muscle, and heart. At
the other end of the spectrum, p19 mRNA was unde-
tectable in prostate, ovary, small intestine, colon, liver,
kidney, and pancreas. Tissue-specific expression was
also seen for p18 (Guan et al., 1994; Figure 5), but with
a pattern distinctly different from that of pi9, partic-
ularly in testis and ovary tissues.
Chromosomal Localization of p19
Using the 1.3-kb full length p19 cDNA as a probe, we
have determined its chromosomal location by fluores-
cence in situ hybridization (FISH) to 19pl3.2 (Figure 6,
CDC2
0 o
0 0p19 0 _ 0
0
0p21 0 0 0 °
1 2 3 4
CDK2
0 0
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Figure 4. p19 inhibits the kinase activity of CDK4 and CDK6.
(A) Inhibition of CDK6-cyclin D2 by p19. The purified recombi-
nant GST-p19 fusion protein (in nanograms) was added to the
activated CDK6-cyclin D2 to assay for its inhibitory activity.
Purified GST-Rb fusion protein was used as a substrate of CDK6-
cyclin D2 kinase. The kinase reaction was resolved on a 10% SDS
gel, and transferred to a nitrocellulose filter, followed by autora-
diography (20-min exposure). (B) Inhibition of CDK4-cyclin D2
kinase activity by p19. The purified recombinant GST-p19 fusion
protein (in nanograms) was added to the activated CDK4-cyclin
D2 to assay for its inhibitory activity. (C) p19 does not inhibit
CDC2- and CDK2-associated kinase activity. Equal amounts of
CDC2 or CDK2 enzymes were immunoprecipitated from Jurkat
cells with an anti-CDC2 or anti-CDK2 antisera and assayed for
kinase activity using histone HI as a substrate in the presence
(lanes 2-4) or absence (lane 1) of purified inhibitor proteins. Both
CDC2 and CDK2 kinase activity was completely inhibited by 100
ng of purified p21 CDK inhibitor protein (lane 4), but not by up
to 400 ng of purified GST-p19 (lanes 2 and 3).
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A-C). Abnormalities in the distal arm of chromosome
19pl3 have been reported in several human tumors, in
particular in ovarian cancer (Kiechle et al., 1994) and
leukemia (Huret et al., 1993). Considering the recent
discoveries that p16 and p15, both homologues of p19,
are deleted or mutated in several specific types of
primary tumors (see reviews in Sherr, 1994; Hunter
and Pines, 1994), the possibility that p19 might encode
a tumor suppressor is clearly worth exploration.
Subcellular Localization of p19
Using affinity-purified antibody raised against a dena-
tured form of p19 protein, we performed indirect im-
munofluorescence to determine the subcellular local-
ization of p19 in Swiss 3T3 cells (see MATERIALS
AND METHODS). This analysis revealed a low level
of p19 present in the entire cell (Figure 7, panel 1A). To
confirm this observation, we transiently transfected
3T3 cells with a p19 overexpression plasmid (pCMV-
p19) and immunostained the transfected cells with the
same anti-p19 antibody. The same distribution of p19
across the whole cell was observed (Figure 7, panel
2A), similar to the endogenous p19 protein. To further
confirm this observation, a different affinity-purified
anti-p19 antibody that was raised against the native
form of a GST-p19 fusion protein was used to immu-
nostain pCMV-pl9-transfected 3T3 cells (Figure 7,
panel 3A). Again, the same p19 distribution pattern






Figure 5. Expression of p19 mRNA in different tis-
sues. Two micrograms of poly(A)+ RNA from 16
different human tissues as indicated at the top of
each lane were hybridized with a 1.3-kb probe de-
rived from full length p19 cDNA. A 1.4-kb discrete
band was detected by this probe as indicated by an
arrow. The same blot was stripped and re-hybrid-
ized with a p18 and a p21 probe.
transfected cells immunostained with both antibodies,
we noticed a lower intensity of p19 staining in the
nucleus. This would suggest that p19 protein may be
predominantly present in the cytoplasm, a possibility
that remains to be confirmed by further study such as
analysis by confocal microscopy. Staining of pCMV-
p19-transfected and -untransfected 3T3 cells with the
pre-immune sera of either of the antibodies or with the
antibodies themselves after pre-incubation with anti-
gen protein did not display any signal (Guan, unpub-
lished observations). A similar observation has also
been made that p16 is localized in both the cytosol and
nucleus (Okamoto et al., 1994; Lukas et al., 1995; Ser-
rano et al., 1995). Distinct from p16 and p19, cyclin Dl
was found to be predominantly localized to the nu-
cleus (e.g., Baldin et al., 1993); Figure 7, panel 4A),
raising the possibility that the different pattern of cel-
lular localization of D-type cyclins and INK4 proteins
may contribute in part to the lack of ternary cyclin
D-CDK4/6-pl6 inhibitor complexes in vivo.
It is worth noting that in the transfection-immunos-
taining experiments all p19 positive cells were single
cells and did not form multi-cell clusters. Because the
immunofluorescence staining was performed 48 h af-
ter transfection, 3T3 cells should have had sufficient
time to complete at least two rounds of cell division
and form clusters containing more than one cell. This
observation indicates that the ectopic expression of
p19 inhibits the cell cycle.




Figure 6. Chromosomal location of p19. (A) After detection of the p19 cDNA probe using FITC-conjugated avidin, the chromosomes were
counterstained with DAPI. The metaphases were imaged using a cooled charge-coupled device camera, and the source images were merged
using Gene Join on an Apple Macintosh computer. (B) Three different chromosomes 19, at a higher magnification, show hybridization of p19
to 19p13. The left hand image of each pair represents the DAPI-stained chromosomes merged with the avidin-FITC signal. The right hand
image of each pair shows the same chromosomes stained with rhodamine-conjugated anti-digoxigenin. The Alu oligo was used to generate
an R-banding pattern that unambiguously localized the p19 hybridization signals to chromosome 19p13. (C) An ideogram of chromosome
19. The bar to the right represents the range of p19 signals.
Cyclins Have Different Effects on the Two CDK
Inhibitor Families' Binding to CDKs
Members of the p16 family (p15, p16, p18, and p19)
and members of the cyclin D family (Dl, D2, and D3)
can both be detected in CDK4 and CDK6 immuno-
complexes. However, reciprocal immunoprecipita-
tions, using antibodies specific to p16 inhibitors or D
cyclins, have yet to detect in vivo interactions between
p16 family inhibitors and cyclin D family members.
Furthermore, coupled IP-Western experiments in ML1
cells using antibodies against p18, p19, and cyclins Dl,
D2, and D3 revealed no p16 family inhibitors in the
cyclin D immunocomplexes and reciprocally no D
cyclins in the inhibitor immunocomplexes (Jenkins
and Xiong, unpublished results). These observations
suggest that these two families of proteins may inter-
act with CDK4/6 in a mutually exclusive manner in
vivo. In contrast, both p21 and p27 can be detected in
CDK and cyclin immunocomplexes, indicating the for-
mation of CDK-cyclin-p21 /p27 ternary complexes.
Using in vitro-assembled CDK6-cyclin Dl complexes,
we further investigated the interaction of both families
of CDK inhibitors with CDK proteins.
Assembly of CDK4/CDK6 with D cyclins using bac-
terially expressed and purified proteins has been
found to be inefficient and requires additional incuba-
tion with mammalian cell lysate or coexpression in
insect cells (Kato et al., 1994b). CDK4 or CDK6 and
cyclin D complexes, however, can be efficiently
assembled using proteins in vitro translated in rabbit
reticulocyte lysate (Figure 8). Equal amounts of in
vitro-translated, [35S]methionine-labeled CDK6 pro-
tein were mixed with increasing amounts of similarly
in vitro-translated, [35S]methionine-labeled cyclin Dl,
followed by the addition of one of two representative
proteins from each of the two CDK inhibitor families.
The mixtures were then immunoprecipitated with an
antibody specific to CDK6 and resolved by SDS-
PAGE. p18 and p19 can each efficiently form binary
complexes with CDK6 in the absence of cyclin Dl
protein (Figure 8A, lanes 1 and 7). Preincubation with
increasing amounts of cyclin Dl protein resulted in a
decreased association of p18 or p19 to CDK6 (Figure
8A, lanes 2-6 and lanes 8-12). These observations
indicated that INK4 proteins interact preferentially
with the unbound CDK6 subunit and that the forma-
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Figure 7. Subcellular localization of p19. (IA) Immunofluorescence staining of untransfected Swiss3T3 cells with affinity purified anti-p19
antibody; (2A) Immunofluorescence staining of pCMV-p19-transfected Swiss3T3 cells with affinity-purified anti-p19 antibody; (3A) Immu-
nofluorescence staining of pCMV-pl9-transfected Swiss3T3 cells with affinity-purified anti-GST-p19 antibody; (4A) Immunofluorescence
staining of untransfected Swiss3T3 cells with affinity-purified anti-cyclin Dl antibody. Column B (DAPI staining for the nucleus) and column
C (phase contrast of cells) correspond to the same field as column A (immunofluorescence staining). I.E. denotes immunofluorescence.
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Figure 8. Opposite effects of cyclin on the binding of the two families of inhibitors to CDK. After sequential incubation of appropriate
proteins, all mixtures were immunoprecipitated with anti-CDK6 antibody and precipitates were resolved by SDS-PAGE followed by
autoradiography. (A) CDK6 was pre-incubated with increasing amounts of c5yclin Dl protein followed by the addition of a set amount of p18
(lanes 1-6) or p19 (lanes 7-12). All proteins were in vitro translated with [3 Slmethionine labeling. (B) CDK6 protein was mixed with equal
amounts of p21 (left) or p27 (right) protein in the absence (lanes 1-7) or presence of increasing amounts of cyclin Dl protein. All proteins were
in vitro translated with [35S]methionine labeling. (C) Preassembled CDK6-p19 binary complexes were incubated with an increasing amount
of cyclin Dl. CDK6 complexes were recovered by immunoprecipitation with an antibody specific to CDK6 and resolved by SDS-PAGE. (D)
Preassembled CDK6-cyclin Dl binary complexes using in vitro-translated [35S]methionine-labeled CDK6 and cyclin Dl proteins were mixed
with an increasing amounts of bacterially produced and purified p19 protein. CDK6 complexes were recovered by immunoprecipitation with
an antibody specific to CDK6 and resolved by SDS-PAGE.
tion of cyclin D1-CDK6 complex interferes with or
prevents this interaction. In contrast, in the absence of
the cyclin subunit, neither p21 nor p27 bind to CDK6
efficiently. Addition of cyclin Dl protein stimulated
the binding of p21 and p27 to CDK6 or CDK6-cyclin
Dl complexes (Figure 8B). This is consistent with re-
cent findings that addition of an increasing amount of
cyclin greatly enhanced the association of p21, p27,
and p57Kip2 with CDK2 (Harper et al., 1995; Matsuoka
et al., 1995). These results demonstrated an opposite
effect of cyclin D protein on the association of the two
families of inhibitors with CDK proteins.
p19 Does Not Disrupt Cyclin D1-CDK6 Association
We next determined whether INK4 proteins and D
cyclins could dissociate each other from CDK4/6. Pre-
assembled CDK6-pl9 binary complexes were incu-
bated with increasing amounts of cyclin Dl protein
and CDK6 complexes were recovered by immunopre-
cipitation with an antibody specific to CDK6 and re-
solved by SDS-PAGE (Figure 8C). Addition of an ex-
cess amount of cyclin Dl protein did not have any
detectable effect on the preassembled CDK6-p19 bi-
nary complex. Reciprocally, addition of an excess
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amount of p19 protein expressed and purified from E.
coli, up to 1 [kg, did not dissociate preassembled
CDK6-cyclin Dl binary complexes either (Figure 8D).
The same results were also obtained for p18 in which
addition of up to 1 ,ug of pl8 protein expressed and
purified from E. coli did not dissociate already assem-
bled CDK6-cyclin Dl binary complexes (our unpub-
lished results). These results indicate that p19 and
cyclin Dl do not dissociate each other's binary associ-
ation with CDK6.
DISCUSSION
In mammalian cells, a number of cell cycle regulatory
proteins have been identified that physically interact
with cyclin or CDK proteins (see reviews by Hunter
and Pines, 1994; Sherr, 1994; Sherr and Roberts, 1995).
Most of these CDK-interacting proteins encode inhib-
itory proteins and they fall into two distinct classes:
the p21 family and the p16 family. In this report, we
isolated and characterized a novel gene encoding a
CDK4- and CDK6-specific inhibitor, pl9INK4d, that be-
longs to the expanding p16/INK4 family of CDK in-
hibitors.
The two families of CDK inhibitors do not share any
detectable sequence similarity and all four isolated
INK4 genes including the newly identified p19 gene
were evolved from a common ancestor. In addition, as
demonstrated in this report the two families of CDK
inhibitors interact with CDKs via distinct mecha-
nisms-while the cyclin subunit stimulates the associ-
ation of p21 and p27 with CDKs or cyclin-CDK
complexes to form ternary p21/p27-CDK-cyclin asso-
ciation, it impedes p19 and p18 (and most likely other
members of this family as well) from binding to CDKs.
The cyclin-dependent binding of p21 to CDK provides
a plausible explanation for the observation that al-
though both p21 and CDC2 proteins are expressed
during S phase, they do not become associated until
the subsequent expression of cyclin Bi protein and the
formation of CDC2-cyclin Bi complexes after the cells
have entered the G2 phase (Li et al., 1994a). These
findings suggest that there may be a sequential change
in the composition of CDK complexes during the cell
cycle: CDKs start as monomeric subunits, assemble
into catalytically inactive p21-CDK-cyclin complexes,
and then convert to active enzymes as the level of
cyclin continues to increase and overcomes the thresh-
old of p21 inhibition. p21 and its two relatives, p27
and p57, are all capable of interacting with multiple
CDK-cyclin complexes, pointing to the possibility that
they may further regulate the activity of these CDK
kinases in a cell cycle-dependent manner by shuffling
from one CDK enzyme to another. Cyclin-stimulated
or cyclin-dependent binding of p21 and p27 to CDKs
suggests that the accumulation of cyclins is critical for
this shuffling, since CDK protein is generally present
in excess throughout the cell cycle, and by itself is ap-
parently not sufficient to release p21 or p27 from-thus
potentially activating-existent cyclin-CDK-p21/p27
complexes. The state of a p21- or p27-inhibited CDK
kinase may thus be dependent on and linked to the
synthesis of the next cyclin in the ordered sequence.
Members of the p16 and cyclin D families can both
form stable binary complexes with CDK6. Purified
protein from the p16 family inhibits the kinase activity
of cyclin D-CDK4/6 heterodimers when added in
vitro (Serrano et al., 1993; Guan et al., 1994; Hannon
and Beach, 1994). This, taken together with the failure
to detect interaction in vivo between members of these
two families, has led to the suggestion that p16 family
inhibitors may inhibit the activity of CDK4 and CDK6
kinases by disrupting cyclin D-CDK4/6 association
(e.g., Guan et al., 1994). Contrary to this prediction,
binary CDK6-cyclin D complexes assembled in vitro
are highly stable and cannot be dissociated by excess
amounts of p19 (Figure 8D) or p18 (our unpublished
results). Although the in vitro setting may lack some
modifications occurring in vivo that could affect the
interaction between inhibitors and cyclin D-CDK4/6
complexes, this seems unlikely to be the case, since the
addition of large excess amounts of purified or in
vitro-translated p18 protein to CEM cell lysate also
had no detectable effect on CDK4- and CDK6-cyclin
Dl binary associations (our unpublished observation).
These observations present a dilemma as to how the
active cyclin D-CDK6 enzyme is inhibited by p19 and
other INK4 proteins. By co-expressing cyclin D2 and
CDK4 in insect cells to allow the assembly of com-
plexes at a high concentration and subsequently incu-
bating with a large amount of purified p19 protein,
Hirai et al. (1995) detected a small amount of p19
protein in cyclin D2 immunoprecipitates concomitant
with inhibition of cyclin D2-CDK4 kinase activity by
p19, indicating the formation of p19-CDK6-cyclin D2
ternary complexes (Hirai et al., 1995). It remains to be
determined, however, whether this represents the pri-
mary mechanism of inhibition by p16 family members
in vivo.
These in vivo observations and the in vitro studies
suggest two different mechanisms for p16 inhibitors to
control the activity of CDK4 and CDK6 both before
and after their activation. The preferential association
of p19 and p18 with unbound CDK6 and the interfer-
ence of D cyclins and p16 inhibitors with each other's
CDK association (Figure 8, C and D) indicate that p16
inhibitors and D cyclins may interact with CDK6 in a
competing or potentially mutually exclusive manner.
Thus, the temporal order of p16 inhibitor and D-type
cyclin expression during the cell cycle may play a key
role in regulating the activity of CDK4 and CDK6 as it
will determine which binary complexes, active cyclin
D-CDK4/6 or inactive pl6-CDK4/6, will be assem-
bled first, and consequently be preferentially main-
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tained. This would provide an inhibitory mechanism
for p16 family proteins not dependent on the ternary
complexes as yet unobserved in vivo. Once they have
already been activated, holo CDK4/6-cyclin D en-
zymes may be inactivated by a p16 inhibitor either
through direct inhibition-the formation of catalyti-
cally inactive ternary p16-cyclin D-CDK4/6 complex-
es-or indirectly, through continuous loss of cyclin D
from the ternary complexes as the result of cyclin D's
short half-life with the consequent accumulation of
binary CDK4/6-pl6 inhibitor complexes that may pre-
vent further binding to and activation of CDK4/6 by
newly synthesized cyclin D.
The p16/INK4 family of CDK inhibitors is ex-
panding rapidly. In addition to four genes that have
already been isolated, several additional CDK4- and
CDK6-associated proteins have also been identified
that are likely to encode p16-related genes (Guan et
al., 1994; Hannon and Beach, 1994; Li et al., 1994b;
our unpublished observation). While these genes
share a common biochemical property in inhibiting
the kinase activity of two closely related CDK en-
zymes, the transcriptional regulation of each mem-
ber of this family is quite different. The p16 gene is
transcriptionally repressed by the retinoblastoma
susceptibility gene product, pRb, and thus forms a
feedback regulatory loop (Li et al., 1994b). The level
of p14/p15MTS2/INK4B mRNA is dramatically in-
creased shortly after the treatment of human kera-
tinocytes with the anti-proliferative agent TGF-,B
(Hannon and Beach, 1994). So far, we have not
observed any effect on the expression of either p18
or p19 mRNA by the inactivation of p53 or pRb
function, or by TGF-f3 treatment (our unpublished
observation). The expression of both p18 and p19
mRNAs, however, exhibits remarkably distinct tis-
sue specificity (Guan et al., 1994; Figure 5), suggest-
ing that p19 and p18 may play a role in inducing
and/or maintaining cell differentiation. Two critical
aspects of cell differentiation are permanent with-
drawal from the active cell division cycle and the
prevention of terminally differentiated cells from
re-entering the cell cycle. CDK4 and CDK6 are two
major CDK enzymes that are activated during, and
required for the Gl progression of the cell cycle,
most likely by phosphorylating and thus downregu-
lating the growth-suppressing activity of pRb. Acti-
vation of a particular INK4 family gene expression
by a specific differentiation signal such as p19 in
hematopoietic cells or p18 in muscle cells could
effectively arrest Gl cell cycle progression to initiate
differentiation. Alternatively, but not mutually ex-
clusively, accumulation of a high level of an INK4
inhibitor may prevent terminally differentiated cells
from re-entering the cell cycle through the same
mechanism.
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